United States Últimas notícias

Ocugen (NASDAQ:OCGN) announced that OCU400 received provisional approval and priority designation in The Bahamas for the treatment of retinitis pigmentosa, an inherited eye disorder.

C4 Therapeutics (NASDAQ:CCCC) presented new biomarker data from two Phase 1 multiple myeloma combination trials evaluating cemsidomide, including studies with dexamethasone and elranatamab.

Fate Therapeutics (NASDAQ:FATE) received a $15 million grant from the California Institute for Regenerative Medicine to support the Phase 2 RECLAIM-LN clinical trial evaluating FT819, an off-the-shelf CAR T-cell therapy.

Madison Dearborn Partners agreed to acquire The Marygold Companies (NYSE:MGLD) in an all-cash transaction that values each outstanding share at $2.00 and will take the financial services company private.

AstraZeneca (NASDAQ:AZN) received U.S. Food and Drug Administration Priority Review for its supplemental Biologics License Application for IMFINZI (durvalumab) combined with enfortumab vedotin in patients with muscle-invasive bladder cancer who are ineligible for or have declined cisplatin-based chemotherapy.

Johnson & Johnson (NYSE:JNJ) reported five-year CARTITUDE-2 study results showing that 10 of 20 patients treated with CARVYKTI remained alive and progression-free without maintenance therapy after receiving a single infusion.

Gilts have fluctuated wildly at the mercy of oil, but the case for hikes remains less clear than in the US thanks to the economy. Bloomberg's Morwenna Coniam joins Guy Johnson and Anna Edwards on 'Bloomberg: The Opening Trade'.

Anna Rosenberg, Amundi Investment Institute Head of Geopolitics, joins Bloomberg's Anna Edwards on "Bloomberg Brief" to discuss the key takeaways from the Trump-Xi Summit, suggesting the US is trying to buy time to reduce its dependence on China.

Merck (NYSE:MRK) and Eisai received U.S. Food and Drug Administration approval for the combination of WELIREG (belzutifan) and LENVIMA (lenvatinib) to treat adults with advanced clear cell renal cell carcinoma after PD-1 or PD-L1 inhibitor therapy.

Duke Energy (NYSE:DUK) appointed Joyce Mullen to its board of directors effective September 28, 2026, with Mullen joining the Audit Committee and Operations and Nuclear Oversight Committee.

Max Kettner, chief multi-asset strategist at HSBC, says it is tough to call an end to rising bond yields as he sees them "incredibly correlated with oil." Kettner asks if there is really any point in buying duration as he looks to tech and equities due to strong earnings. He speaks on "Bloomberg Brief."

Addex Therapeutics (NASDAQ:ADXN) announced it regained full global rights to its GABAB positive allosteric modulator assets from Indivior UK, including a development candidate previously selected under their research collaboration.